On Wednesday the 12th of April, 2017, the Chairman & CEO of Agenus Inc. picked up shares in his own company. He made two large buys with a total value of $330,000 over the past couple of days according to the filing (filing 1 & filing 2). Our system alerted us yesterday after market close of this insider trade.
When we look at the chart of $AGEN we notice one thing that worries us. The stock recently dropped through a multiple bottom, which is usually a very negative sign. Overall, it seems to be trending down very clearly since October last year. On the other hand, our system didn’t alert us for no reason. It is a double insider purchase from a good insider. He has purchased more shares in the past and most of the time the stock went up afterwards. Furthermore, we see a good amount of volume of this stock so we don’t have to worry about not being able to sell shares if it isn’t going to be a success. The low average volatility worries us a little bit, but still we feel that it is worth a shot. We are buying and hoping to get a quick profit of around 8% to 10%. At the same time we will set a stop loss at $3.00 and will keep an eye at this trade. If it doesn’t go up in the coming days, close your position and move on to the next trade.
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body’s immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3. In addition, the company develops vaccine programs, such as Prophage cancer vaccine candidate; AutoSynVax, a synthetic cancer vaccine program targeting the neo-epitope landscape in cancer patients; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a novel class of tumor specific neo-epitopes. Further, Agenus Inc. develops QS-21 Stimulon, a saponin-based vaccine adjuvant that has completed Phase III clinical trials for the treatment of malaria and shingles. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
February was a big month for the stock market as a whole, but BIGGER for us.
Although the S&P 500 index is setting a new all-time high record and the Nasdaq keeps pushing higher and higher, legal insider buying transactions are pushing the limits of what is possible.
Here is a quick overview of what some of our recent alerts did in one daytoday:
Unfortunately not too many people have profited from this amazing rally … Even with the markets going up, most of the investors are still losing money.
The NUMBER ONE REASON for this is the lack of time to research the market and pick the right stocks. That we can solve, however!
As you probably know, our way of investing is very simple. Whenever an insider buys a significant amount of shares of its own company, we buy as well. We usually sell within the following month, making quick, juicy returns.
Do we follow all insider buying activity? No, definitely not, only the ones that meet all of our criteria. Since we have started trading insider buys many years ago, we have a hit rate of 80%.
Does this mean that 80% of our picks are winners? Yes it certainly does!
And it gets even better, a lot of our picks gain more than 10% within one month after the alert. Double your portfolio in 2014 like we do every year since we started.
It is impossible for us to lie about the performance of our alerts, as we report insider buying activity as it is legally filed.
So what are you waiting for? Just sign up for a 14 day free trial and check it out. It is a regular Credit Card subscription for 0 dollars for the first 14 days and you can cancel any time!
January! A time when I always get giddy about the coming year, although market analysts are wetting their panties for what is to come. Supposedly, it will be a very volatile year and indices will not end up much higher. Who cares :). Volatility is a good thing for insider buying and we do not really care about the overall market anyway. We like inside buying!
January is a slow month. Not only traditionally, but we think the big investment banks might have scared some of the insiders off too. Every year it is the same story: market this, market that, bla bla bla. Did you know that almost every investment bank said that the market would go up by 10 percent last year? Well, it didn’t. It went up a lot higher. It could have tanked for all we know. No one can predict the future. We can’t either!
The difference however, is that we are not actively trying to bite of more than we can chew. We are not out there analyzing the effects of the Fed’s tapering on the overall market or China’s impact on the gold price and how everything ties together. Even when your analysis makes sense, it has no predictive power. None. Whatsoever. Statistically proven.
What we did do, is look at what statistics did prove. The fact that legal insider buying activity is often associated with a stock price increase for example. If there are people with some predictive power in our opinion, they are the people leading the individual companies on the stock market. Does the stock price always go up after an insider buy takes place? No. Does it often go up? Yes. Especially with some of the criteria that we add to the mix. Every day a lot of insider buying activity happens, but that event might not have an impact on a stock like IBM for example. So we do not report it in our Premium E-mail Alerts.
This week Seacoast Banking Corp ($SBCF) provided us with another nice bump to add to the mix!
Will every month be a killer month? No. Will over time, the returns of this strategy outperform the returns of the market and reliably get me to move the needle for your capital. Yes. Very much so! For newcomers to our community, check out our monthly reports, check out our blog posts. This is all verifiable information. We hide nothing, because there is nothing to hide. If an insider buys and the stock fits our criteria, it lands in our Premium Alerts Subscriber’s inbox. Boom. Done. Next!
Although both stocks posted decent highs inside May of +8.45% and +19.35% respectively, June was really where the action was about to happen. Let’s take another look at Limelight Networks (LLNW) and Geron Corporation (GERN) to make clear what insider buying activity is all about. Stock prices do not really care about dates as much as people do as you can see below.
BOOM! +41% on LLNW and +69% on GERN! See what I mean here? This is the kind of information you miss when only looking at snapshots. +41% and +69% from the time of our alerts looks completely different figures than what we saw in May alone, of course.
So what happened here? Well in short LLNW won an 8-year old patent infringement court case in early June, and the FDA removed the hold on GERN’s cancer research clinical trial in the middle of June. We first alerted LLNW on May 22nd and GERN on May 12th in real-time at $2.13 and $1.86 respectively when significant insider buying had just taken place in both companies.
For new readers: this is the kind of price action you get when following insider buying activity. So many statistical studies have proven the edge insiders have and, as a consequence, investors who follow them closely (that is why we do it in real-time) and on top of that there are plenty of anecdotal stories like the above that underline that insiders do know more.
Because this is not the millionth profitable coincidence, of course, and you can bet your pinky that these things will keep happening with a lot of stocks spiking as a result. From our perspective we just let it all happen and we are going to keep profiting from this happily and safely. Sign up for a Free Trial by clicking the button below if you have not already!